Skip to main content
. 2015 Jul 29;35(12):2021–2031. doi: 10.1038/jcbfm.2015.167

Figure 2.

Figure 2

The effect of receptor-associated protein, inactivated recombinant tissue-type plasminogen activator, SU1498, or sunitinib on EB extravasation. The effect of receptor-associated protein (RAP; A), SU1498 (C), or sunitinib (D) on EB extravasation in mice treated with recombinant tissue-type plasminogen activator (rt-PA) at 4 hours after permanent middle cerebral artery (MCA) occlusion. The rt-PA or inactive rt-PA (B) was administered at 10 mg/kg. Vehicle indicates treatment with solvent only (B). The RAP was intravenously administered at 1 or 2 mg/kg, 5 minutes before rt-PA treatment. The SU1498 was intraperitoneally administered at 10 or 20 mg/kg, 5 minutes after rt-PA treatment. Sunitinib was intravenously administered at 10 or 20 mg/kg, 5 minutes after rt-PA treatment. Bars represent median values. *P<0.05 (Mann–Whitney U-test). EB, Evans blue; RAP, receptor-associated protein.